← Back to headlines
Molecular Partners Presents on DLL3-Targeting Radio-DARPin MP0712 in Phase 1 Trials
Molecular Partners held presentations at ASCO and SNMMI 2026 regarding their DLL3-Targeting Radio-DARPin MP0712, which is currently dosing patients in Phase 1 clinical trials.
30 May, 12:00 — 30 May, 12:00
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Anthropic Suspends AI Models Mythos and Fable for Foreign Nationals on US National Security Order
24m ago
Hybe Apologizes for BTS World Tour Delay in Busan
42m ago
Appeals Court Upholds Sam Bankman-Fried's FTX Fraud Conviction
48m ago